611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO, CA
Ex-99.1
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Quince Therapeutics Reports Financial Condition as of December 31, 2025
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
Provides Business Update and Reports Third Quarter 2025 Financial Results
Reg. FD
Material disclosure
Notice of Late Filing for Annual Report
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload